EXEL - Exelixis begins phase 1 trial of XL114 to treat non-hodgkin's lymphoma

Exelixis (NASDAQ:EXEL) said it had started dose-escalation for phase 1 trial of its anti-cancer compound, XL114, to treat non-Hodgkin’s lymphoma (NHL), in patients who had received prior standard therapies. The company said the objectives of the study will be to determine the recommended dose and/or the maximum tolerated dose of XL114. The company licensed XL114 from Aurigene Discovery Technologies Limited under the companies’ July 2019 collaboration, option and license agreement. More than 80,000 people will be diagnosed with NHL in 2022, making it the seventh most common cancer in the U.S, according to the American Cancer Society. (EXEL) up +0.5%

For further details see:

Exelixis begins phase 1 trial of XL114 to treat non-hodgkin’s lymphoma